The Latest Cardiac and Vascular News
– Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for heart failure, regardless of ejection fraction – FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. with heart failure with preserved ejection fraction, […]
Commercial Launch Readiness Activities Underway for Omecamtiv Mecarbil in Advance of PDUFA Date of November 30, 2022 SEQUOIA-HCM Open to Enrollment; Development Program for Aficamten Expanding in 2022 Company Provides 2022 Financial Guidance; More Than 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Cytokinetics, […]
MEMPHIS, Tenn., Feb. 25, 2022 (GLOBE NEWSWIRE) — Modern Vascular, the national leader in minimally invasive treatment for Peripheral Artery Disease (PAD), expands its footprint with its newest clinic at 5645 Murray Ave., in Memphis. Board-Certified Vascular and interventional Radiologist, Samuel G. Putnam III, MD, FSIR, will manage the new clinic. […]
Q4 2021 reported revenue of $278.5 million, up 7.9% on a reported basis and up 8.4% on a constant currency revenue, organic* basis, compared to Q4 2020 Q4 2021 GAAP EPS increased 32% year-over-year to $0.36, compared to $0.27 in Q4 2020 Q4 2021 non-GAAP EPS* increased 31% year-over-year to […]
PRAIRIE VILLAGE, Kan., Feb. 24, 2022 /PRNewswire/ — Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced the hiring of Dan Tamez as Senior Director of Nonclinical and Clinical Research and the engagement of Geoff Tansley, PhD as Senior R&D Consultant. Tamez will lead nonclinical […]
SILVER SPRING, Md., Feb. 24, 2022 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control […]
Exceeded 2021 financial guidance with revenues of more than $800 million Webcast today, February 24, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif., Feb. 24, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year ended December 31, 2021, and recent business achievements. “During 2021, we […]
Extensive analysis for U.S. by MedStar Health Research Institute determined icosapent ethyl is cost-effective compared to standard of care, both during the REDUCE-IT® clinical trial period and over a lifetime projection BRIDGEWATER, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — JAMA Network Open has published “Cost-effectiveness of Icosapent Ethyl for High-risk Patients With […]
SAN FRANCISCO, Feb. 23, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three months and full year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights Revenue of $81.8 million, […]
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, […]
